NTV Asset Management LLC Has $1.60 Million Stake in Becton, Dickinson and Company (NYSE:BDX)

NTV Asset Management LLC lifted its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 11.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,494 shares of the medical instruments supplier’s stock after purchasing an additional 661 shares during the quarter. NTV Asset Management LLC’s holdings in Becton, Dickinson and were worth $1,596,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD raised its position in Becton, Dickinson and by 25.7% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 12,982,788 shares of the medical instruments supplier’s stock valued at $3,157,284,000 after buying an additional 2,654,142 shares during the last quarter. State Street Corp grew its stake in Becton, Dickinson and by 2.3% in the second quarter. State Street Corp now owns 12,219,978 shares of the medical instruments supplier’s stock valued at $2,971,776,000 after purchasing an additional 269,994 shares in the last quarter. Morgan Stanley boosted its stake in shares of Becton, Dickinson and by 16.9% during the 2nd quarter. Morgan Stanley now owns 9,175,000 shares of the medical instruments supplier’s stock worth $2,231,268,000 after acquiring an additional 1,323,224 shares during the period. Massachusetts Financial Services Co. MA boosted its stake in shares of Becton, Dickinson and by 2.1% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 4,533,981 shares of the medical instruments supplier’s stock worth $1,102,620,000 after acquiring an additional 93,388 shares during the period. Finally, Fiera Capital Corp boosted its stake in shares of Becton, Dickinson and by 0.5% during the 2nd quarter. Fiera Capital Corp now owns 3,839,772 shares of the medical instruments supplier’s stock worth $918,743,000 after acquiring an additional 17,344 shares during the period. 83.98% of the stock is currently owned by institutional investors.

Several research firms recently issued reports on BDX. Zacks Investment Research upgraded Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $250.00 price target for the company in a research note on Tuesday, October 19th. Morgan Stanley boosted their price target on Becton, Dickinson and from $285.00 to $300.00 and gave the company an “overweight” rating in a research note on Friday, January 7th. Piper Sandler cut Becton, Dickinson and from an “overweight” rating to a “neutral” rating and dropped their price objective for the company from $285.00 to $260.00 in a report on Wednesday, December 8th. Finally, SVB Leerink reaffirmed a “market perform” rating on shares of Becton, Dickinson and in a report on Friday, October 22nd. Five analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $269.63.

NYSE:BDX traded down $0.82 during mid-day trading on Friday, hitting $262.87. 7,298 shares of the company’s stock were exchanged, compared to its average volume of 1,102,170. The company has a 50 day simple moving average of $249.04 and a 200-day simple moving average of $248.95. The company has a current ratio of 1.33, a quick ratio of 0.90 and a debt-to-equity ratio of 0.72. Becton, Dickinson and Company has a fifty-two week low of $235.13 and a fifty-two week high of $265.23. The firm has a market capitalization of $74.93 billion, a P/E ratio of 38.49, a PEG ratio of 2.88 and a beta of 0.72.

Becton, Dickinson and (NYSE:BDX) last issued its quarterly earnings results on Thursday, November 4th. The medical instruments supplier reported $2.59 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.45 by $0.14. Becton, Dickinson and had a net margin of 10.22% and a return on equity of 15.97%. The firm had revenue of $5.10 billion for the quarter, compared to the consensus estimate of $4.91 billion. During the same quarter in the previous year, the company earned $2.79 EPS. The company’s revenue for the quarter was up 6.6% on a year-over-year basis. As a group, analysts expect that Becton, Dickinson and Company will post 12.41 earnings per share for the current year.

The business also recently declared a quarterly dividend, which was paid on Friday, December 31st. Investors of record on Friday, December 10th were issued a $0.87 dividend. This represents a $3.48 dividend on an annualized basis and a dividend yield of 1.32%. The ex-dividend date of this dividend was Thursday, December 9th. This is a boost from Becton, Dickinson and’s previous quarterly dividend of $0.83. Becton, Dickinson and’s payout ratio is 50.80%.

Becton, Dickinson and declared that its Board of Directors has initiated a share repurchase plan on Thursday, November 4th that allows the company to buyback 10,000,000 outstanding shares. This buyback authorization allows the medical instruments supplier to reacquire shares of its stock through open market purchases. Stock buyback plans are often an indication that the company’s board of directors believes its shares are undervalued.

In other Becton, Dickinson and news, EVP Betty D. Larson sold 3,341 shares of Becton, Dickinson and stock in a transaction that occurred on Thursday, December 16th. The stock was sold at an average price of $255.00, for a total value of $851,955.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP Thomas J. Spoerel sold 233 shares of Becton, Dickinson and stock in a transaction on Tuesday, December 7th. The stock was sold at an average price of $250.00, for a total transaction of $58,250.00. The disclosure for this sale can be found here. Insiders own 0.50% of the company’s stock.

Becton, Dickinson and Profile

Becton, Dickinson & Co is a medical technology company. The firm engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public.

Recommended Story: Why is total return important?

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.